We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-25.4%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.39B
AUM Growth
-$1.3B
Cap. Flow
-$39.5M
Cap. Flow %
-1.65%
Top 10 Hldgs %
47.64%
Holding
157
New
7
Increased
9
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$25.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
3
VIGL
Vigil Neuroscience
VIGL
+$14.8M
4
IGMS
IGM Biosciences
IGMS
+$9.31M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.83M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$18.8M
2
NG icon
NovaGold Resources
NG
+$17.8M
3
ALBO
Albireo Pharma Inc
ALBO
+$14M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.7M
5
KRYS icon
Krystal Biotech
KRYS
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.06%
2 Consumer Discretionary 6.64%
3 Miscellaneous 0.97%
4 Financials 0.85%
5 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LVTX
126
DELISTED
LAVA Therapeutics
LVTX
$880K 0.04%
200,000
– –
APLT
127
DELISTED
Applied Therapeutics
APLT
$844K 0.04%
400,000
– –
KLDO
128
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$826K 0.03%
500,500
– –
CRVS icon
129
Corvus Pharmaceuticals
CRVS
$1.09B
$820K 0.03%
500,000
– –
INKT icon
130
MiNK Therapeutics
INKT
$58.2M
$652K 0.03%
28,959
– –
LITS
131
Lite Strategy Inc
LITS
$37.1M
$603K 0.03%
50,000
– –
MTCR
132
DELISTED
Metacrine, Inc. Common Stock
MTCR
$564K 0.02%
924,898
– –
SGTX
133
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$406K 0.02%
21,231
– –
KA
134
DELISTED
Kineta, Inc. Common Stock
KA
$326K 0.01%
31,056
– –
ATXS
135
DELISTED
Astria Therapeutics
ATXS
$224K 0.01%
33,333
– –
DNA icon
136
Ginkgo Bioworks
DNA
$471M
$202K 0.01%
+1,250
New +$243K
CDTX
137
DELISTED
Cidara Therapeutics
CDTX
$187K 0.01%
11,234
– –
BMY icon
138
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-1,000,000
Closed -$62.4M
C icon
139
CALL
Citigroup
C
$228B
– –
-1,000,000
Closed -$60.4M
DLO icon
140
dLocal
DLO
$4.25B
– –
-20,000
Closed -$714K
GDS icon
141
GDS Holdings
GDS
$6.1B
– –
-100,000
Closed -$4.72M
IQ icon
142
iQIYI
IQ
$965M
– –
-1,000,000
Closed -$4.56M
NG icon
143
NovaGold Resources
NG
$3.18B
– –
-2,600,000
Closed -$17.8M
PHAT icon
144
Phathom Pharmaceuticals
PHAT
$660M
– –
-200,000
Closed -$3.93M
RIGL icon
145
Rigel Pharmaceuticals
RIGL
$829M
– –
-32,110
Closed -$851K
RIVN icon
146
Rivian
RIVN
$22.5B
– –
-7,000
Closed -$726K
SYRE icon
147
Spyre Therapeutics
SYRE
$8.02B
– –
-41,800
Closed -$4.96M
VRTX icon
148
CALL
Vertex Pharmaceuticals
VRTX
$130B
– –
-100,000
Closed -$22M
XBI icon
149
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-1,000,000
Closed -$112M
DCPH
150
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-100,000
Closed -$977K
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2022 Portfolio in Review

As of Q1 2022, Artal Group held 157 positions worth $2.39B, down 35% from $3.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group's Q1 2022 filing shows 7 new, 9 increased, 11 reduced and 20 closed positions. Its largest new stake was Vigil Neuroscience: 1,121,191 shares worth $7.88M. The largest sale was Amicus Therapeutics, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q1 2022 buy was Vigil Neuroscience: 1,121,191 shares worth $7.88M.
  • Artal Group added most to argenx in Q1 2022, an estimated $25.4M increase.
  • Artal Group's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $18.8M.
  • Artal Group fully exited NovaGold Resources in Q1 2022, selling an estimated $17.8M.
  • Artal Group's ten largest holdings make up 48% of its $2.39B portfolio in Q1 2022.
  • Artal Group opened 7 new positions and closed 20 in Q1 2022.
  • Artal Group's portfolio value fell 35% quarter-over-quarter to $2.39B.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.